Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tanimilast - Chiesi Farmaceutici

Next Previous
Search
Drug Profile

Tanimilast - Chiesi Farmaceutici

Alternative Names: CHF 6001 NEXThaler DPI; CHF 6001 NEXThaler®; CHF-6001; CHF6001 DPI

Latest Information Update: 03 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chiesi Farmaceutici
  • Class Antiallergics; Antiasthmatics; Benzoates; Chlorinated hydrocarbons; Fluorinated hydrocarbons; Phenyl ethers; Pyridines; Small molecules; Sulfonamides
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Chronic obstructive pulmonary disease
  • Phase II Allergic asthma; Asthma

Most Recent Events

  • 31 Mar 2025 Chiesi Farmaceutici plans a phase II trial in Asthma (In adolescents, In adults, In the elderly) in Bulgaria (Inhalation) (NCT06900816) (EUCT2024-516483-29-00 )
  • 18 Mar 2025 Phase-I clinical trials in Chronic obstructive pulmonary disease (In volunteers) in Bulgaria (Inhalation) (NCT06892756)(EudraCT2024-516475-32-00)
  • 18 Mar 2025 Chiesi Farmaceutici plans a phase I pharmacokinetics trial (In volunteers) (Inhalation, Powder) in March 2025 (NCT06892756)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top